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Abstract Complex Regional Pain Syndrome (CRPS) is a
neuropathic pain syndrome, which involves glial activation
and central sensitization in the central nervous system. Here,
we describe positive outcomes of two CRPS patients, after
they were treated with low-dose naltrexone (a glial attenu-
ator), in combination with other CRPS therapies. Prominent
CRPS symptoms remitted in these two patients, including
dystonic spasms and fixed dystonia (respectively), following
treatment with low-dose naltrexone (LDN). LDN, which is
known to antagonize the Toll-like Receptor 4 pathway and
attenuate activated microglia, was utilized in these patients
after conventional CRPS pharmacotherapy failed to suppress
their recalcitrant CRPS symptoms.
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Introduction
Complex Regional Pain Syndrome (CRPS), formerly
known as Reflex Sympathetic Dystrophy (RSD) is a
neuroinflammatory condition that is characterized by a com-
bination of sensory, autonomic, vasomotor, and motors
dysfunctions. One of the characteristic symptoms of this
condition is that the pain is out of proportion to the initial
injury. Diagnoses of CRPS are often delayed because it is
under recognized (Binkley 2012). If effective treatments are
given early enough in progression of the disease, there is
reduced chance for the spread of regional pain, autonomic
dysfunction, motor changes, and negative sensory symptoms,
such as hypoalgesia (Marinus et al. 2011). As CRPS
progresses, it becomes refractory to sympathetic nerve
blocks, conventional analgesics, anticonvulsants and
antidepressants.
During neuroimmune activation, TLR4 (Toll-Like
Receptor 4) is upregulated in microglia, resident immune cells
of the central nervous system (Watkins et al. 2009). After
transection of the L5 spinal nerve in the rat, TLR4 expression
is increased in spinal microglia. This correlates with the rodent
developing neuropathic pain (Tanga et al. 2005). From a post-
mortem analysis of a CRPS patient, activated microglia and
astroglia in the central nervous system (CNS) have been
implicated in the generation of CRPS symptoms (Del Valle
et al. 2009).
Activation of TLR4 in both microglia and CNS neurons
augments the production of pro-inflammatory cytokines via
the NF-κB pathway (Milligan and Watkins 2009; Leow-
Dyke et al. 2012). NF-kB is a multi-functional transcription
factor that is activated by c-Jun-N-terminal kinase (JNK),
extracellular signal-related kinase (ERK), or p38 (Milligan
and Watkins 2009). In activated glia and neurons, NF-κB
activity promotes the production of pro-inflammatory cyto-
kines and neurotoxic superoxides (Milligan and Watkins
2009; Leow-Dyke et al. 2012; Fellner et al. 2013), which
act as mediators for neuropathic pain, as well as other
neurological dysfunctions (Liu et al. 2000; Barbosa et al.
2012; Besedovsky and del Rey 2011). Pro-inflammatory
cytokines, as well as the neurotrophin BNDF (brain-derived
neurotrophic factor), induce enhanced excitatory tone and
diminished inhibitory tone in nociceptive neural networks,
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leading to hyperalgesia or allodynia (von Hehn et al. 2012).
Sustained TLR4 stimulation in microglial populations can
also lead to neuronal injury and death (Fellner et al. 2013).
In rodents, the TLR4 antagonist, naltrexone, is able to
suppress allodynia arising from bone cancer (Mao-Ying et
al. 2012). In rodents, naltrexone is able to cross the blood–
brain barrier, suppress glial cell activation, and reverse neu-
ropathic pain arising from chronic constriction nerve injury
(Hutchinson et al. 2008).
A recent study reports that low-dose oral naltrexone
reduces pain in fibromyalgia patients (Younger and
Mackey 2009). Low-dose naltrexone (LDN) refers to doses
approximately 50-fold lower than doses of naltrexone typically
given to patients addicted to opioids (Rea et al. 2004; Younger
and Mackey 2009).
Opiate antagonists differ from opioids through a replace-
ment of the characteristic N-methyl group with a
N-cyclopropyl, N-allyl group. At low concentrations,
naltrexone is able to antagonize TLR4 on activated glial
cells, without inhibiting other opioid receptors in the
CNS (Hutchinson et al. 2008). This allows endogenous
anti-nociceptive pathways involving μ-receptors to continue
operating.
A recent paper has reported positive benefit of ibudilast,
an oral glial attenuator, for the treatment of neuropathic pain
in several CRPS patients (Rolan et al. 2009). Below, we
describe positive outcomes of two CRPS patients treated
with low-dose naltrexone, in combination with other CRPS
therapies. Low-dose naltrexone was utilized in these
patients after more conventional CRPS pharmacotherapy
failed to suppress their recalcitrant CRPS symptoms. Each
patient met IASP criteria for the diagnosis of CRPS.
Case 1. Clinical course and treatment
A 48 year-old male veteran sustained an injury to his right
leg in 2006. While undergoing aqua-therapy, he injured his
right great toe, which subsequently became infected.
Following drainage of an abscess and removal of the great
toe’s nail, the patient developed the following CRPS symptoms
in his right lower extremity: swelling, allodynia (pain to normal
touch), color change, temperature change, and some weakness.
By 2007, the patient developed moderate CRPS symptoms in
his upper extremities. In 2008, he developed blisters and skin
ulceration in his right lower extremity (Fig. 1). At this time, the
patient was being treated with opioids, pregabalin, and
duloxetine.
By 2009, the patient’s pain had become severe enough
that he could not ambulate without assistance. He developed
muscle spasms in the right upper extremity. In 2010, he
underwent a cardiac bypass surgery for coronary artery
disease. His CRPS symptoms became widespread after this
surgery, spreading to his upper chest, upper arms, and
forearms. In 2011, the patient developed significant dystonic
spasms to both upper extremities, resulting in hyperextension
of his fingers. From 2008 to 2012, the patient underwent
multiple treatments with anticonvulsants, antidepressants,
physical therapy, psychotherapy, topical and systemic
analgesics, including but not limited to opioids. The patient
also currently has diabetes mellitus type II, hypertension,
hyperlipidemia, as well as coronary artery disease.
In August of 2011, the patient began low-dose intrave-
nous ketamine infusions. He reported a good initial re-
sponse, but the relief was not sustained. He continued to
have ketamine booster infusions at intervals of 4 to 6 weeks.
Although the patient engaged in aggressive physical therapy
during this time, his maximum interval of relief from pain
following a given ketamine infusion decreased to an interval
of 3 weeks. In January 2012, his use of the opioid oxyco-
done was changed to tapentadol. This narcotic was removed
for 1 week prior to starting low-dose naltrexone, which was
started and maintained at 4.5 mg per day (1 dose at night).
Additional medications included: metformin, tramadol,
valsartan, cloazepate, simvastatin, fish oil, and vitamin C.
Immediately before LDN treatment, the patient had
patchy areas of allodynia to the medial and dorsal aspect
of his right foot, extensive areas of dysesthesia in his right
lower extremity below the knee and heel of his foot, as well
as bilaterally dysesthesia in the upper extremities. There
were significant color and temperature changes in the right
foot compared to the left foot, as well as pitting edema in the
right foot. A triple-phase bone scan revealed significant
reuptake in the right foot, characteristic of CRPS.
By March of 2012, the patient’s requirements for the
lower dose intravenous ketamine infusions were not as
frequent (6 week intervals, pain spikes not as high). The
patient recovered from CRPS flares more quickly, felt more
energetic, and tolerated pain better. He became physically
more active, and his sleep improved significantly. Within
2 months after starting LDN, the patient’s dystonic spasms
discontinued, although he still had moderate pain in both
upper extremities. The patient was able to walk without a
cane (Fig. 2b), which he had used continuously since 2006.
His pain was an average of 8 to 10 on the Numeric Rating
Scale (NRS) before starting LDN. It dropped down to an
average of 5 to 6 on the NRS after starting LDN. After LDN
therapy, the patient’s pain symptoms have reduced in severity,
but not in their distribution. His current mood state is good. No
side effects of LDN were noted.
Case 2. Clinical course and treatment
A female patient, currently 12 years old, has a genetic
disorder, Ehlers-Danlos Syndrome (EDS) hypermobility
type 1, dysautonomia, non-epileptic seizures, chronic gastritis,
mitochondrial dysfunction, asthma, vision loss, thyroid tumor
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and anti-cardiolipin antibodies. As a result of her EDS, the
patient has had repeated dislocations of her right shoulder, as
well as her right ankle. The patient first developed CRPS in
her lower right extremity in 2008. In 2009, the patient developed
dystonic muscle spasms in the upper extremities, which were
interpreted by her physicians as evidence of a conversion
disorder.
The patient was first seen by one of us (PC) in February
of 2011. Her symptoms of CRPS included color change,
increased temperature in the right foot (90 °C) versus (82 °C)
in the left foot, allodynia over the dorsum of right foot, and
patchy areas of dysesthesia over her right leg. She also had
areas of allodynia and dysesthesia in the left lower extremity
and both upper extremities, as well as distorted nails on the
right foot. When first seen, the patient’s medications were
levetiracetam, midodrine, baclofen, trazodone, diphenhydra-
mine, lansoprazole, budesonide, levalbuterol, L-Carnitine,
coenzymeQ10, vitamin D, vitamin C, magnesium, and vitamin
B complex. She rated her pain on a NRS (Numerical Rating
Scale) as 8/10 at its lowest and 10/10 at its worst. In early 2011,
the patient experienced a subluxation of her right ankle. The
lower right leg and ankle subsequently developed fixed
dystonia, with plantar flexion and varus (Fig. 3a).
In June 2011, the patient was started on low dose naltrexone
(LDN) of 3 mg once a day and ketamine troches (sublingual)
10 mg on as needed basis. The LDN was increased to 4.5 mg
per day, 4 weeks after starting it. LDN was started as a lower
dose to gauge tolerability. She tolerated the LDN very well with
Fig. 1 Advanced CRPS
symptoms in Case 1. 4.5 years
after onset of the disorder. a
Allodynia and pronounced
vasomotor dysfunction are
present in the lower right
extremity (photo taken 9/18/
2008). b One week later, the leg
has developed numerous
ulcerations
Fig. 2 Case 1. Certain symptoms are attenuated following treatment
with low-dose naltrexone (LDN) in a long-standing case of CRPS
(6 years after onset). a Allodynia is greatly reduced in both legs after
LDN. However, bilateral trophic changes remain in the lower extrem-
ities. Slight swelling is present in the distal portion of the right foot.
Within 2 months of treatment with LDN, the patient was able to bear
full body weight, and walk without assistance. Before LDN, the patient
utilized a cane for 6 years. b One year after LDN treatment, the patient
still has persistent long-term trophic changes in the skin of both lower
extremities (taken 1/16/2013)
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no reports of adverse effects. Her pain scores dropped from
NRS (7–10)/10, to (3–5)/10. She also reported a decrease in
allodynia, as well as a decrease in sensitivity to touch and
temperature change. There was no effect on the dystonia.
Two months after starting LDN, she underwent 400 units of
botulinum toxin A injections to the right gastrocnemius group
of muscles with minimal relief of her dystonia. The right lower
extremity was placed in an above knee cast for 6weeks. Several
weeks after the cast was removed, the patient subluxated her
right ankle again. She underwent a 400 units injection of
botulinum toxin, and a cast was applied again. The patient used
ketamine troches (10 mg) for 3 weeks after the LDN was
started, as needed for pain. She was taking ketamine troches
on as needed basis for acute flare-ups of her CRPS pain. This
was limited to no more than 30mg of ketamine troches per day.
The patient progressively reduced her use of ketamine troches
3 weeks after starting LDN, and by 8 weeks was taking them
rarely.
In December of 2011, she underwent percutaneous pinning
of the right ankle to stabilize the joint. The pins were removed
6 weeks later and the ankle joint subluxated again. In February
of 2012, the patient underwent reinforcement to the right ankle
with cadaver ligaments. She continued to be on low dose
naltrexone during this time, except for 4 perioperative days,
during which the LDN was discontinued. As per institutional
protocol, LDN was stopped for 24 h before surgery. After
surgery, she was given oral opioids (hydrocodone with
acetaminophen) for 1 week. The oral opioids were then
discontinued, and LDN treatment was resumed 24 h,
after her last dose of opioid. The patient noticed a decrease
in her post-operative pain, ranging from (4–6)/10, 3 weeks
after resuming LDN. Skin discoloration and allodynia
could not be assessed after the surgery because her leg
was in a cast.
At the time of cast removal, the patient’s lower leg and
ankle had a normal range of motion, indicating a remission
of the leg’s fixed dystonia (Fig. 3b). The leg had a slight red
color at the time of cast removal, but no allodynia. Ten
months after surgery, the patient’s gait was normal.
Remarkably, the patient did not experience any spread of
her CRPS, despite undergoing multiple invasive procedures,
including surgery. One of the known triggers for a CRPS
flare-up, or spread of CRPS symptoms, is trauma
(Schwartzman et al. 2009; van Rijn et al. 2011). The patient
still has a chronic shoulder dislocation, associated with her
EDS. However, her CRPS symptoms have resolved
completely. The patient has been maintained on LDN for
18 months. No side effects of LDN have been noted.
Discussion
Causalgia, which is often a salient feature of CRPS, has long
been viewed as having a neuroinflammatory etiology
(Mitchell 1872; Sudeck 1901). Although centralized
neuropathic pain has been connected to activated glia
in rodents (Milligan and Watkins 2009), it is an open
questionwhether the symptoms in CRPS in humans are linked
to activated glia in the CNS. The positive responses of the two
patients discussed above to LDN are among the first reported
benefits of glial attenuators for CRPS symptoms. A prior
study described moderate pain benefit to several CRPS
patients enrolled in a clinical trial of ibudilast, another
glial attenuator that is unrelated to LDN in its molecular
action (Rolan et al. 2009).
In the patient of Case Study 1, dystonic spasms developed
in the upper extremities 1 year after the onset of CRPS in the
right lower extremity. The spread of CRPS symptoms,
including movement disorders, may involve a spread of
neuroinflammation within the neuraxis (Del Valle et al.
2009; Cooper 2011; Cooper and Clark 2012). Altered cyto-
kine involvement has also been postulated to contribute to
the spread of symptoms in CRPS patients (Linnman et al.
2012). Distortion of somatotopic maps (Maihöfner et al.
2003, 2004), deficient drive from the parietal cortex to the
supplemental motor and primary motor corticies (Maihöfner
and Peltz 2011), bilateral disinhibition of intracortical
inhibition (Schwenkreis et al. 2003), disinhibited spinal
Fig. 3 (Case 2) Fixed dystonia,
allodynia, and vasomotor
abnormalities in the right lower
extremity of a CRPS patient
(panel a) remitted following
treatment with a low-dose
naltrexone. b No symptoms and
signs of CRPS after LDN
treatment. Two months after
surgical reinforcement of the
right ankle for Ehlers-Danlos
Syndrome (EDS)
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reflexes, and paresis of affected extremities, are known
functional impairments of CRPS patients (Birklein et al.
2000; van Hilten et al. 2001, 2011; Schouten et al. 2003;
van Hilten 2010; Kolb et al. 2012). CNS neuroinflammation
has also been postulated to generate functional movement
disorders in inflammatory neurological disorders other than
CRPS (Church et al. 2004; Sansing et al. 2007; van de
Warrenburg et al. 2007). By attenuating activated CNS glia
systemically, LDN may be especially useful for the treatment
of CRPS symptoms, some of which might be generated by
spreading neuroinflammation within the neuraxis (e.g. fixed
dystonias, Cooper and Clark 2012).
In Case 1, repeated ketamine infusions were not adequate
to drive the patient’s CRPS symptoms into remission.
Therefore, LDN was added to his polypharmacy. Ketamine
blocks NMDA glutamate receptors, whereas LDN acts on
Toll-Like Receptors in activated glia. These two medica-
tions would not be expected to interact at similar molecular
sites, but would be expected to complement each other
actions in suppressing hyperexcitable nociceptive neurons.
Ketamine would be expected to act rapidly and directly on
NMDA receptors in glutamatergic synapses, whereas LDN
would be expected to act more slowly and indirectly by
suppressing the neuroinflammatory activities of activated
glia, which alter the excitability of nociceptive neuronal
networks through the release of sensitizing agents, such as
the neurotrophin BDNF (Coull et al. 2005).
In neurons, extracellular signal-related kinase (ERK) is
activated through the TLR4 pathway. ERK can further
sensitize excited AMPA and NMDA receptors, leading
to neuropathic pain (Milligan and Watkins 2009). By
attenuating TLR4 signaling, LDN could have an indirect
inhibitory action on the activity of AMPA and NMDA
receptors in sensitized glutamate-receptive neurons.
NMDA receptors (NMDARs) are also present in activat-
ed microglia. NMDARs stimulation can activate microglia
in vitro, as well as contribute to their neuroinflammatory
response (Kaindl et al. 2012). In human patients with
centralized neuroinflammation, such as CRPS (del Valle
et al. 2009), a therapeutic combination of ketamine and
LDN (through their respective ionotrophic and metabotrophic
actions) might synergistically suppress the pro-inflammation
paracrine signaling activities of activated microglia.
Glial attenuators are likely to provide benefits in control-
ling CNS neuroinflammation that arises from periphery
nerve injury, CNS injury, or autoimmune attack on CNS
targets. However, it is possible that inhibiting CNS
neuroinflammation with glial attenuators might be deleterious
to immuno-compromised individuals, or individuals with an
ongoing viral or bacterial infection. However, naltrexone has
been used in HVC and HIV patients to treat opioid addiction,
without causing major complications (Mitchell et al. 2012). In
general, before utilizing LDN in a given individual,
practitioners should be aware that atypical cases of CRPS
and movement disorders have been linked to infectious
agents, such as Borrelia burgdorferi (Lyme disease) (Sibanc
and Lesnicar 2002) and parvovirus B19 (Fong and de Sousa
2006; Grillo and da Silva 2009). The safety of using LDN to
attenuate neuroinflammation, pain, and movement disorders,
in these particular infectious diseases is unknown.
The patient of Case 1 experienced CRPS symptom
improvement within 4 weeks after starting LDN, including a
cessation of his dystonic spasms in his upper extremities.
Although the patient continues to obtain sustained benefit
from LDN, chronic underlying drivers may be maintaining
this patient’s CRPS symptoms. For instance, autoimmune
attack on certain neurotransmitter receptors in the peripheral
and central nervous system are implicated in CRPS. A recent
study found that 90 % of adult CRPS patients had either
autoantibodies against the beta-2 adrenergic receptor, or the
M2 muscarinic acetylcholine receptor (Kohr et al. 2011). LDN
would not be expected to block the primary steps of an
autoimmune attack on these neurotransmitter receptor targets.
Instead, LDN would be expected to attenuate proinflammatory
reactions of microglia that would likely be activated in a
neuroimmune attack.
The fixed dystonias, which frequently occur in CRPS
patients, are sometimes viewed as symptoms of a psycho-
genic illness—a pathology originating in the mind (such as
conversion disorder) (Ochoa and Verdugo 1995; Verdugo
and Ochoa 2000; Hawley and Weiner 2011). This presumed
etiology for CRPS dystonia can restrict treatment options to
psychotherapy. Other treatment options are available. Intra-
thecal baclofen, for instance, is effective for upper extremity
CRPS dystonia, but not for lower extremity CRPS dystonia
(van Hilten et al. 2000). Deep brain stimulation (DBS) has
recently been used for multi-focal dystonia in CRPS patients
(Javed et al. 2011). Positive results from these approaches
provide evidence that CRPS dystonias are responsive to
physiological interventions.
Fixed dystonia in the lower extremity has been very
difficult to treat in CRPS patients (van Hilten et al. 2000;
Raja 2009). Physical therapy (PT) is a first-line intervention
for the fixed dystonias of CRPS, however, the limited range
of motion of these dystonias often limit the effectiveness of
PT. Botulium toxin injections have been reported to suppress
dystonia in the shoulder and upper extremities of CRPS
patients (Kharkar et al. 2011a, b). However, there are no
publications that report success of botulinum injection therapy
in the lower extremities of CRPS patients.
The dystonic lower leg of the CRPS patient in Case 2
required a multi-modal treatment approach.Without reduction
of the subluxed fixed dystonic posture, recalcitrant dermal
ulcerations, and/or focal osteopenia might have resulted from
interrupted blood flow to the affected extremity. Sublingual
ketamine and low-dose naltrexone were given prior to casting,
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to reduce the risk of CRPS symptom spread, and to reduce
central sensitization, which was presumed to be already
present in the patient’s nervous system.
Moderate reduction of pain in fibromyalgia patients
takes place within days after treatment with LDN
(Younger and Mackey 2009). For the two patients described
in this current report, improvement of CRPS symptoms
occurred within 2–4 weeks after receiving LDN. In
CRPS patients, pain may require longer periods of
time to subside, because CRPS patients have multiple
interlocking and overlapping pathophysiologies, including
structural damage to peripheral tissues (e.g. focal loss
of bone density, small fiber neuropathies, and vascular
damage) (Fig. 1) (Moriwaki et al. 1997; Oaklander and
Fields 2009).
Remission of fixed dystonia, along with other CRPS
symptoms, such and allodynia and vasomotor abnormalities,
could be readily interpreted as a physiological response
linked to LDN therapy, as opposed to effects produced
by psychological suggestion. However, it is clear that a
randomized, blinded clinical trial is needed to exclude a
psychogenic mechanism of action of LDN in CRPS
patients. CRPS patients do have unusual psycho-active
nociceptive, autonomic, and motor symptoms, which
can be provoked by psycho-perceptional conflicts (Cohen
et al. 2012; Bailey et al. 2012). LDN may be a useful
tool to determine whether these psycho-active symptoms
of CRPS patients are indicative of functional neurological
disorders, which may be secondary to neuroinflammatory
lesions in the CNS (Cooper and Clark 2012).
Conclusion
Our use of LDN treatment for CRPS patients was motivated
by a presumed neuroinflammatory etiology for long-
standing CRPS symptoms. The remission of pain and dys-
tonic spasms in Case 1, as well a remission of all CRPS
symptoms (including fixed dystonia) in Case 2, provide
evidence that a multi-modal interventional approach, which
includes low-dose naltrexone (a known glial attenuator),
should be considered as a treatment option for the treatment
of CRPS patients, particularly those patients with dystonic
movement disorders.
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